PTEN encodes a lipid phosphatase that is underexpressed in many cancers owing to deletions, mutations or gene silencing 1-3 . PTEN dephosphorylates phosphatidylinositol (3,4,5)-triphosphate, thereby opposing the activity of class I phosphatidylinositol 3-kinases that mediate growth-and survival-factor signalling through phosphatidylinositol 3-kinase effectors such as AKT and mTOR 2 . To determine whether continued PTEN inactivation is required to maintain malignancy, here we generate an RNA interference-based transgenic mouse model that allows tetracycline-dependent regulation of PTEN in a time-and tissue-specific manner. Postnatal Pten knockdown in the haematopoietic compartment produced highly disseminated T-cell acute lymphoblastic leukaemia. Notably, reactivation of PTEN mainly reduced T-cell leukaemia dissemination but had little effect on tumour load in haematopoietic organs. Leukaemia infiltration into the intestine was dependent on CCR9 G-protein-coupled receptor signalling, which was amplified by PTEN loss. Our results suggest that in the absence of PTEN, G-protein-coupled receptors may have an unanticipated role in driving tumour growth and invasion in an unsupportive environment. They further reveal that the role of PTEN loss in tumour maintenance is not invariant and can be influenced by the tissue microenvironment, thereby producing a form of intratumoral heterogeneity that is independent of cancer genotype.
PTEN encodes a lipid phosphatase that is underexpressed in many cancers owing to deletions, mutations or gene silencing [1] [2] [3] . PTEN dephosphorylates phosphatidylinositol (3, 4, 5) -triphosphate, thereby opposing the activity of class I phosphatidylinositol 3-kinases that mediate growth-and survival-factor signalling through phosphatidylinositol 3-kinase effectors such as AKT and mTOR 2 . To determine whether continued PTEN inactivation is required to maintain malignancy, here we generate an RNA interference-based transgenic mouse model that allows tetracycline-dependent regulation of PTEN in a time-and tissue-specific manner. Postnatal Pten knockdown in the haematopoietic compartment produced highly disseminated T-cell acute lymphoblastic leukaemia. Notably, reactivation of PTEN mainly reduced T-cell leukaemia dissemination but had little effect on tumour load in haematopoietic organs. Leukaemia infiltration into the intestine was dependent on CCR9 G-protein-coupled receptor signalling, which was amplified by PTEN loss. Our results suggest that in the absence of PTEN, G-protein-coupled receptors may have an unanticipated role in driving tumour growth and invasion in an unsupportive environment. They further reveal that the role of PTEN loss in tumour maintenance is not invariant and can be influenced by the tissue microenvironment, thereby producing a form of intratumoral heterogeneity that is independent of cancer genotype.
Stable RNA interference using short-hairpin RNAs (shRNAs) provides a powerful approach for studying tumour suppressor gene activity in vitro and in vivo [4] [5] [6] . To explore the role of PTEN loss in tumour maintenance, we developed shRNA transgenic mouse lines targeting Pten using miR-30-based shRNAs expressed from an inducible tetracyclineresponsive element promoter 6 ( Fig. 1a and Extended Data Fig. 1 ). Murine embryonic fibroblasts (MEFs) obtained from embryonic day (E)13.5 embryos of shPten;R26-rtTA2 double-transgenic mice displayed reversible knockdown of Pten upon doxycycline (Dox) addition and withdrawal, which correlated with increased AKT phosphorylation following insulin stimulation ( Fig. 1b and Extended Data Fig. 1c ). As expected 7, 8 , Dox-treated mice expressing shPten in multiple tissues developed several tumour types including T-cell malignancies (Extended Data Fig. 1e-i) .
Owing to the high frequency of T-cell disease in the shPten mice and the frequent inactivation of PTEN in human T-cell acute lymphoblastic leukaemia (T-ALL) 9 , we focused on the effects of PTEN suppression and reactivation in the lymphoid compartment. We crossed mice transgenic for an shRNA against luciferase (shLuc) and shPten mice to a Vav-tTA transgenic line, which expresses a 'Tet-off' Tet transactivator in early B and T cells 10 and drives shRNA expression in a manner that is silenced upon Dox addition (Extended Data Fig. 2 and data not shown). The Vav-tTA;shPten mice displayed thymic hyperplasia (Extended Data Fig. 2a-d ) and, by 16 weeks, a subset deteriorated and had to be euthanized ( Fig. 1c ), whereas control animals remained healthy (P , 0.001). Diseased mice showed massive enhanced green fluorescent protein (eGFP)-positive tumours that consisted of Thy1.2 1 CD4 1 CD8 1 doublepositive T cells filling the thoracic cavity and infiltrating spleen, lymph nodes as well as extrahematopoietic organs like the liver, kidney and intestine ( Fig. 1d , Extended Data Figs 2e, f and 3a, and data not shown). shPten-expressing tumours demonstrated marked Pten knockdown and increased AKT phosphorylation comparable to Pten-null T-cell malignancies ( Fig. 1e, see 4 Howard Hughes Medical Institute, New York, New York 10065, USA. 5 Institute of Human Genetics, Medical University of Graz, A-8010 Graz, Austria. 6 Human T-ALLs with PTEN loss often overexpress MYC and can harbour NOTCH1 and CDKN2A mutations 12 . Analysis of murine shPtenexpressing tumours by spectral karyotyping, comparative genomic hybridization (CGH) and sequencing of the gene encoding the T-cell receptor b-chain showed that most primary tumours were clonal and harboured the same recurrent translocations between the Tcra locus and Myc observed in a Pten knockout model and a small subset of human T-ALL (Extended Data Figs 3b, c and 4a, and data not shown) 13, 14 . One shPten T-ALL showed a Cdkn2a deletion by CGH and six out of eight tumours analysed showed activating mutations in the Notch1 PEST domain ( Fig. 1e and Extended Data Figs 3c, d and 4b). Gene set enrichment analysis (GSEA) of gene expression profiles obtained from shPten leukaemia demonstrated enrichment for a human PTEN-mutated T-ALL signature, and profiles from human PTEN-mutated T-ALLs were enriched for a murine shPten signature (Extended Data Fig. 5a, b) . Thus, although all the T-cell leukaemias were initiated by a Pten shRNA, they acquire molecular features reminiscent of the human disease 12, 13, 15 .
The leukaemia arising in shPten mice was highly malignant, and rapidly produced disease when transplanted into recipient mice (Extended Data Fig. 6a ). Of note, because the Vav-tTA;shPten transgenic mice were of a mixed genetic background, Rag1 2/2 recipients were used to avoid graft rejection. These recipients succumbed to a highly disseminated form of T-ALL consisting of CD4 1 CD8 1 double-positive cells that rapidly took over the haematopoietic organs, accumulated to high levels in the peripheral blood, and spread to the liver, kidney and intestine ( Fig. 2d and Extended Data Fig. 6b ). Notably, decreased PTEN levels were associated with disease dissemination and lower survival in T-ALL patients ( Fig. 1f and Extended Data Fig. 6c ), and were also linked with intestinal infiltration in patients with peripheral T-cell lymphoma (Extended Data Fig. 6d, e ). The association between PTEN loss and disease dissemination in murine and human T-cell malignancies underscores the relevance of the model to human disease.
We reasoned that the transplanted leukaemias described above would be ideal for our experiments as they are highly malignant such that individual primary isolates can be studied for their response to different perturbations in multiple secondary recipients. Recipients were monitored for disease development by weekly analysis of peripheral blood for the presence of eGFP 1 (shPten-expressing) cells. Upon disease manifestation, a cohort of mice was given Dox to silence the shRNA and reactivate PTEN. Notably, Dox treatment almost tripled the survival time of mice harbouring Vav-tTA;shPten leukaemia ( Fig. 2a ; P , 0.0001) but had no effect on mice harbouring Pten 2/2 leukaemia (Extended Data Fig. 6f ). Immunoblotting of leukaemic cells collected from mice indicated that the system worked as expected: hence, Dox addition led to upregulation of Pten messenger RNA (Extended Data Fig. 7a -c and data not shown), silenced eGFP and re-established PTEN to endogenous levels ( Fig. 2b and Extended Data Fig. 7d ). Therefore, PTEN reactivation had a marked anticancer effect but was by no means curative.
Leukaemia-bearing mice showed magnetic resonance imaging (MRI) signals in multiple haematopoietic compartments, the liver and intestine (Extended Data Fig. 6h , i and data not shown). Although PTEN reactivation had no overt effect on tumour growth in the lymph nodes or spleen, it visibly decreased tumour infiltration into intestine and liver ( Fig. 2c and Extended Data Fig. 6g -i). These findings were corroborated by immunohistochemistry (IHC) and flow cytometric quantification of CD4 1 leukaemic cells ( Fig. 2e, f) . Notably, Dox treatment had a minimal impact on the proliferation or apoptosis of leukaemic cells residing in the lymph nodes and spleen, but triggered apoptosis in leukaemic cells that had disseminated into the intestine ( Fig. 2g and Extended Data Fig. 7e-g) . Thus, the impact of PTEN expression on disease progression is dictated by the anatomical location of the leukaemic cell.
We next assessed the phosphorylation state of key phosphatidylinositol 3-kinase (PI3K) effectors in tissue sections by IHC and pathway functionality by positron emission tomography (PET) of 18 F-fluorodeoxyglucose (FDG) uptake into leukaemia cells 16 . The heterogeneous responses correlated with the ability of PTEN to effectively suppress aberrant PI3K signalling: whereas S6 and AKT phosphorylation were reduced in disseminated leukaemic cells obtained from the intestine, it persisted in the leukaemic cells collected from the spleen of the same animal ( Fig. 3a and Extended Data Fig. 8 ). Similarly, mice displayed a marked reduction in FDG signal stemming from the liver and intestine within 2 days of PTEN reactivation, an effect that could not simply be accounted for by loss of leukaemia burden (Fig. 3b, c) . Conversely, the FDG signal emanating from the spleen and bone marrow remained strong (Fig. 3b, d and Supplementary Videos 1 and 2). The divergent responses to PTEN , or untreated controls (Pten off; n 5 15), P , 0.0001 by log-rank test. b, Western blot analysis of splenic tumour cells from control, untreated, and mice treated with Dox for 5 days. c, Brightfield and eGFP images of lymph nodes and spleen from an untreated mouse (Pten off) and mouse treated with Dox for 5 days (Pten on) (n 5 10). d, Flow cytometric analysis of CD4, eGFP and CD8 expression in tumour cells from the peripheral blood of mice 6 Dox for 5 days (n 5 10). e, IHC analysis for CD3 expression in the spleen, liver and small intestine from shPten T-ALL transplanted mice 6 Dox for 5 days (n 5 3 per group). Scale bars, 100 mm, 20 mm in insets. f, Relative tumour infiltration in the indicated organs of transplanted Rag1 2/2 mice off (n 5 7) and on (n 5 7) Dox, quantified by flow cytometric analysis of CD4 1 cells; *P , 0.05, **P , 0.01 by Student's t-test (6 s.d.). g, IHC staining for cleaved caspase 3 (CC3) in the spleen and intestine from mice 10 days after transplant with shPten T-ALL either left untreated or treated with Dox for 36 h. Representative sections from one of three mice per cohort are shown. Scale bars, 100 mm, 20 mm in insets.
LETTER RESEARCH
activation in a clonal leukaemia suggest that the control of the PI3K pathway can be markedly affected by microenvironmental factors. Surprisingly, untreated NCr nude mice transplanted with the same number of shPten tumour cells survived as long as Rag1 2/2 recipient mice treated with Dox, and did not show a survival advantage following Dox addition (Fig. 4a ). The untreated NCr recipients displayed vastly reduced intestinal dissemination of leukaemic cells compared to normal and thymectomized Rag1 2/2 recipients ( Fig. 4b and Extended Data Fig. 9a , b, g, h), whereas spleen and lymph nodes were strongly affected ( Fig. 4c and Extended Data Fig. 9c, d) . Apparently, genetic differences between Rag1 2/2 and NCr mice contribute to variation in disease aggressiveness and the response to PTEN reactivation.
Whereas Rag1 
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expression of Ccl25 (refs 18, 19) , which encodes a chemokine that is mainly expressed by epithelial cells in the thymus and small intestine and acts as an important chemoattractant for T cells in the gut 20, 21 . CCL25 acts through CCR9, a G-protein-coupled receptor that can signal through the PI3K pathway and is expressed on a subset of developing thymocytes 22, 23 . Signalling through a related receptor, CCR7, is important for leukaemia dissemination into the central nervous system 24 ; moreover, the CCL25/CCR9 network is required for T-cell dissemination during inflammatory bowel disease, which can be countered by CCR9 antagonists currently in clinical trials 25, 26 . CCL25 levels were decreased in the intestine of NCr mice (Extended Data Fig. 9e , f), whereas CCR9 was highly expressed on the shPten leukaemia cells (Fig. 4d ). Notably, CCR9 expression was not affected by PTEN reactivation as determined by fluorescence-activated cell sorting and RNA-seq analysis (Extended Data Fig. 9i and data not shown).
To test whether PTEN influences T-ALL homing and survival in the intestine by modulating CCL25 signalling, shPten T-cell leukaemia isolates were treated with CCL25 (6 Dox to modulate PTEN), and cell signalling and motility was assessed in short-term culture. Whereas CCL25 stimulation had little impact on PI3K signalling in the presence of PTEN, Pten knockdown sensitized cells to CCL25-induced AKT phosphorylation and, to a lesser extent, S6 phosphorylation ( Fig. 4e ). Similar results were obtained with two human T-ALL lines transduced with either shPTEN or a control shRNA ( Fig. 4f and Extended Data Fig. 9j ). CCL25 addition also increased migration of murine shPten T-ALL cells in a transwell assay, and the effect was largely abrogated by PTEN reactivation (Extended Data Fig. 9k ).
Dual-colour in vivo competition experiments were performed to assess the contribution of CCR9 signalling to T-ALL dissemination (Fig. 4g ). After identifying shRNAs efficient at knocking down Ccr9 (Extended Data Fig. 10a, b ), eGFP 1 shPten leukaemic cells were transduced with either shCcr9 or shRenilla control shRNAs co-expressing the mCherry red fluorescent protein ( Fig. 4g and Extended Data Fig. 10d ). Upon transplantation and subsequent disease development, mice were euthanized and the fraction of eGFP/mCherry 1 cells versus all eGFP 1 cells was determined in various organs ( Fig. 4g, h ). shCcr9-expressing T-ALL cells showed significantly decreased abundance in the intestine but not the spleen or liver ( Fig. 4h and Extended Data Fig. 10c, d ). Mice transplanted with shPten leukaemic cells were also treated with a small molecule inhibitor for CCR9 that is in clinical trials for the treatment of inflammatory bowel disease 26 . Although the effects on survival were modest, leukaemia dissemination was reduced in the intestine, whereas cells in the spleen and liver were unaffected (Extended Data Fig. 10e -h and data not shown). Hence, in the intestine, PTEN suppression promotes leukaemic cell dissemination and maintenance by modulating CCL25-CCR9 signalling.
In human cancers, PTEN deletions often coincide with tumour expansion, metastasis and a generally worse prognosis 9,27,28 , results confirmed and extended for T-cell disease in this report. Using a powerful new mouse model enabling reversible suppression of endogenous PTEN expression, we show that PTEN loss can promote tumour cell survival at distant sites by amplifying weak environmental cues that enable tumour cells to survive in an otherwise non-supportive microenvironment. Accordingly, the promiscuous yet passive ability of PTEN to attenuate PI3K signalling 2 may be influenced by the nature and intensity of phosphatidylinositol (3,4,5)-triphosphate-generating signals in different microenvironments, and targeting such tissue-specific signals might present a valid strategy to treat cancer spread. Still, the requirement for PTEN loss in tumour maintenance is not absolute and can be influenced by genetic context 29, 30 and, as shown here, the tumour microenvironment. These observations paint a more complex picture of how PTEN inactivation drives tumour maintenance, and reveal an interplay between tumour and microenvironment that would not be predicted from studies on cultured cells. Nonetheless, this interplay produces a form of intratumoral heterogeneity that is independent of genotype but can affect disease progression and perhaps the clinical response to molecularly targeted therapies.
METHODS SUMMARY
ES cell targeting and generation of Pten shRNA transgenic mice. KH2 ES cells expressing the reverse transactivator (rtTA2) from the Rosa26 promoter were electroporated with Pten shRNAs cloned into a recombination-mediated cassette exchange vector (cTGM) targeting the Col1a1 locus 6 , and correctly targeted and functional ES cell clones were identified and used to generate live mice by tetraploid embryo complementation. The number of each shRNA is used as index and refers to the position of the first nucleotide of the shRNA guide strand relative to the refseq cDNA sequence. MEFs were generated from 13.5-day-old embryos according to standard protocols. Mice were bred to CMV-rtTA, CAGGS-rtTA and Vav-tTA transactivator lines to generate heterozygous (for example, shPten 1/2 ;CMV-rtTA 1/2 ) double-transgenic mice using standard breeding techniques. To induce shRNA expression, Pten and firefly luciferase (Luc) or Renilla luciferase (Renilla) shRNA mice bred to CMV-rtTA or CAGGS-rtTA mice were put on food containing 625 mg kg 21 Dox (Harlan Teklad) immediately after weaning. Dox food was also used to shut off shRNA expression in Vav-tTA transgenic animals at different time points. All mouse experiments were performed in accordance with institutional and national guidelines and regulations and were approved by the Institution Animal Care and Use Committee (IACUC no. 06-02-97-17 (Cold Spring Harbour Laboratory) and no. 11-06-017 (Memorial Sloan Kettering Cancer Center)).
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. Author Information Data sets from RNA-seq analysis were deposited at the Sequence Read Archive (SRA) at the European Nucleotide Archive under the accession number PRJEB5498. Reprints and permissions information is available at www.nature.com/ reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to S.W.L. (lowes@mskcc.org).
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METHODS
Constructs and shRNAs. To identify potent shRNAs targeting murine and human Pten, various 97-bp oligonucleotides predicted from sensor-based and other shRNA design algorithms (Extended Data Fig. 4c and data not shown) 31, 32 were XhoI-EcoRI cloned into the miR-30 cassette of the MLP vector and tested as described previously (Extended Data Fig. 1a ) 33 . The two most efficient murine Pten shRNAs (Pten.1522 and Pten.2049, numbers refer to the position of the first nucleotide of the shRNA guide strand relative to the refseq cDNA sequence) were cloned into a recombination-mediated cassette exchange (RCME) vector (cTGM) targeting the Col1a1 locus (see Fig. 1a ) 6, 34 . For knockdown of human PTEN, the Pten.1522 shRNA, which showed complete overlap with the human PTEN sequence, was used. For knockdown of murine Ccr9, multiple shRNAs were designed, cloned and tested as described above. The two most efficient shRNAs, shCcr9.904 (97-mer: 59-TGCT GTTGACAGTGAGCGCAAGGATAAGAATGCCAAGCTATAGTGAAGCCA CAGATGTATAGCTTGGCATTCTTATCCTTATGCCTACTGCCTCGGA-39) and shCcr9.2357 (97-mer: 59-TGCTGTTGACAGTGAGCGCCCCAACAGTTT ACAACCTTTATAGTGAAGCCA CAGATGTATAAAGGTTGTAAACTGTTG GGATGCCTACTGCCTCGGA-39), were cloned into a LMN-cherry vector (MSCV-miR30-pgk-NeoR-IRES-mCherry) for dual-colour competition assays (see below). ES cell targeting and generation of transgenic mice. Two potent shRNAs against murine Pten were cloned into a cassette that links eGFP and shRNA expression downstream of TRE, and targeted into a defined locus downstream of the collagen, type I, alpha 1 (Col1a1) gene in KH2 ES cells expressing the reverse transactivator (rtTA2) from the Rosa26 promoter 34 by RMCE ( Fig. 1a and Extended Data Fig. 1a ) 6, 34 . Southern blotting showed correct transgene insertion, and Dox-inducible knockdown of endogenous PTEN was confirmed by western blot analysis (Extended Data Fig. 1b ).
Germline transgenic mice were generated by tetraploid embryo complementation. MEFs were generated from 13.5-day-old embryos according to standard protocols. Since both shRNAs caused a similar degree of Pten knockdown and PI3K pathway activation and equally promoted tumorigenesis in in vivo transplantation experiments (Extended Data Fig. 1c, d and data not shown), we focused subsequent analysis on a single (shPten.1522) transgenic line.
Mice were bred to CMV-rtTA, CAGGS-rtTA and Vav-tTA transactivator lines 6,10,35 to generate compound heterozygous or homozygous (for example, shPten 1/2 ;CMV-rtTA 1/2 or shPten 1/1 ;Vav-tTA 1/1 ) double-transgenic mice using standard breeding techniques. To induce shRNA expression, Pten and firefly luciferase (Luc) or Renilla luciferase (Renilla) shRNA mice bred to CMV-rtTA or CAGGS-rtTA mice were put on food containing 625 mg kg 21 Dox (Harlan Teklad) immediately after weaning. As predicted from knockout mice 7, 36 , most double-transgenic mice harbouring the inducible shPten allele together with the broadly expressing CMV-rtTA or the CAGGS-rtTA3 transactivator strains 6, 35 developed tumours within 12 months of Dox addition (Extended Data Fig. 2 ; data not shown). Dox food was also used to shut off shRNA expression in Vav-tTA transgenic animals at different time points. For the Vav-tTA;shPten mice survival studies, a number of Vav-tTA 1 ;shPten 1 mice (n 5 49) and controls (Vav-tTA 1 ;shLuc 1 (n 5 20), Vav-tTA 1 ;shPten 2 (n 5 68), Vav-tTA 1 ;shPten 1 , 1 Dox (n 5 10)) were generated and analysed. No difference in phenotype was observed between heterozygous (shPten 1/2 ;Vav-tTA 1/2 ) and homozygous (shPten 1/1 ;Vav-tTA 1/1 ) mice. All mouse experiments were performed in accordance with institutional and national guidelines and regulations and were approved by the Institution Animal Care and Use Committee (IACUC no. 06-02-97-17 (Cold Spring Harbour Laboratory) and no. 11-06-017 (Memorial Sloan Kettering Cancer Center)). Statistics and reagents. For all murine survival studies, a group size of at least five animals per condition was chosen, which allowed the detection of twofold differences in survival with a power of 0.89, assuming a two-sided test with a significance threshold a of 0.05 and a standard deviation of less than 50% of the mean. For the primary animals, all mice with the correct genotype were included in the analysis. For the transplantation experiments, all mice receiving similar amounts of transplanted cells as determined by flow cytometric and/or whole-body immunofluorescent evaluation 5-10 days after transplant were included in the analysis. For the reactivation and treatment experiments, animals were assigned into different groups by random picking from the non-selected transplanted group of mice 5-10 days after transplant. Blinding of animals in the reactivation/inhibitor treatment studies was not feasible, because of requirements by the local animal housing facility to mark cages if containing special food/treatment.
Appropriate statistical tests were applied as indicated, including non-parametric tests for experiments where sample size was too small to assess normal distribution. All t-tests and derivatives were two-sided. For all tests, variation was calculated as standard deviation and included in the graphs as error bars. To investigate whether PTEN expression has an impact on tumour dissemination in human T-ALL, we performed IHC staining for PTEN on bone marrow sections from 31 patients with newly diagnosed T-ALL, for which clinical data on disease dissemination was available.
Owing to the relatively low number of patient specimens and because the variables were nonlinear, we analysed the data in a contingency table using Fisher's exact test. We also re-analysed the contingency table using Berger's test, with similar results 37 . For probing an association between PTEN expression status and intestinal infiltration in human T-cell lymphoma patients, the same statistical tests were applied.
All antibodies used for western blot analysis were purchased from Cell Signaling Technology unless otherwise specified, including the antibodies against PTEN (cat no. 9188), pAKT(S473, cat no. 4060), pAKT(T308, cat no. 2965), AKT (cat no. 4691), S6 (cat no.2317), pS6(S235/236, cat no. 4858), cleaved Notch1 (cat no. 4147). For intracellular flow cytometric analysis of pS6(S235/236) directly, Pacific-Blue fluorescence-coupled antibodies were purchased from Cell Signaling (cat no. 8520).
Antibodies for flow cytometry were purchased from BioLegend unless otherwise specified. Mouse antibodies included CD3 (clone 145-2C11), CD4 (clone GK1.5), CD8 (clone 53-6.7), Thy1.2 (clone 30-H12), CD45 (clone 30-F11), CCR9 (clone 9B1), CD11b (clone M1-70), Gr-1 (clone RB6-8C5), CD44 (clone IM7), CD25 (clone PC61).
Human T-ALL cell lines HBP-ALL and TALL1 were a kind gift from I. Aifantis. All cell lines were tested for absence of mycoplasma and authenticated by flow cytometry and western blotting. Transplantation experiments. For transplantation, single-cell suspensions were generated from primary tumours and 1 3 10 5 cells were injected into sublethally (450 rad) irradiated recipient female Rag1 2/2 (on a C57B6 background, cat no. 2216) or NCr nude mice (on an inbred albino background, cat no. 2019) via tail vein injection. All mice used as transplant recipients were purchased from Jackson Laboratory. Mice were monitored by serial flow cytometric analysis of the peripheral blood. Once eGFP 1 cells reached .5% of total leukocytes, cohorts of mice were started on Dox containing food as indicated. Analysis of human T-ALL and PTCL patient samples. For the analysis of survival of PTEN normal versus PTEN altered patients with T-ALL, published genomic and mRNA expression data on patients with T-ALL was used (accession number GSE28703) 15 (7), T/NK cell lymphoma (4), angioimmunoblastic T-cell lymphoma (9) , anaplastic large cell lymphoma (14) , and peripheral T-cell lymphoma with non bowel or gastrointestinal tract involvement (46) . All samples were consecutively ascertained at the Memorial Sloan-Kettering Cancer Center (MSKCC) between 2001 and 2012. Use of tissue samples were approved with an Institutional Review Board Waiver and the Human Bio-specimen Utilization Committee. All biopsies were evaluated at MSKCC, and the histological diagnosis was based on H&E staining. The PTEN antibody (rabbit monoclonal antibody from Cell Signaling, 138G6, no. 9559) was used at a 1:30 dilution. IHC analysis was performed on the Ventana Discovery XT automated platform according to the manufacturer's instructions. Results were scored as 0, 1, 2 for PTEN with 0 5 no staining of tumour cells, with endothelial cell-and macrophage-positive; 1 5 weak staining of tumour cells, compared to endothelial cell-and macrophage-positive; 2 5 strong staining of tumour cells, compared to endothelial cell-and macrophage-positive. Representative images were taken using the Olympus BX41 model, DP20 camera, at 360 objective. MRI. The mice were anesthetized with 2-3% isoflurane delivered in O 2 and allowed to breathe spontaneously during the imaging study. The mice were positioned supine in a custom-made acrylic cradle fitted with a snout mask for continuous delivery of anaesthesia. Non-invasive, MRI-compatible monitors (pulse-oximetry, respiratory rate and rectal temperature probe, SA Instruments) were positioned for continuous monitoring of vital signs while the animal underwent MRI imaging. During imaging, body temperature was kept strictly within 36.5-37.5 uC using a computer-assisted air heating system (SA Instruments). All imaging was performed on a 9.4T/20 MRI instrument interfaced to a Bruker Advance console and controlled by Paravision 5.0 software (Bruker Biospin). A volume radiofrequency coil (diameter 11.2 mm) used in transmit and receive mode were used for all imaging acquisitions. Following localizer anatomical scout scans, a 2D multi-slice T2-weighted RARE sequence along the coronal slice direction with fat suppression was obtained with the following parameters: TR 5 12,500 ms, TE 5 40 ms, RARE factor 5 8, NA 5 8, FOV 5 6.0 3 6.0 cm 2 (256 3 256), yielding an in-plane resolution of 0.234 3 0.234 mm 2 , slice thickness 5 0.9 mm total scanning time 5 10 min 40 s. 18 F-FDG-PET analysis. For PET analysis, mice were fasted for 6 h before intravenous injection of 0.5 mCi 18 F-FDG. Mice were kept for 1 h under isoflurane anaesthesia and subsequently imaged on a Focus 120 microPET (Siemens) or in LETTER RESEARCH some cases an Inveon MicroPET/CT (Siemens). Image normalization and analysis was performed using the ASI Pro MicroPET analysis software and the Inveon Workplace software package (Siemens Medical Solutions). CGH. CGH experiments were performed using standard Agilent 244k mouse whole genome arrays, and hybridizations were carried out according to the manufacturer's recommendations. Data processing, normalization and segmentation were carried out as described 39 . Multiplex-FISH (M-FISH)/spectral karyotyping analysis. Cells were cultured in RPMI-1640 with L-glutamine (PAA) supplemented with 10% FBS, 1% penicillinstreptomycin, 50 mM mercaptoethanole, 50 U ml 21 human interleukin 2 and 5 mg ml 21 concanavalin A for 48-72 h at 37 uC and 5% CO 2 . To prepare metaphases, colcemid at a final concentration of 0.1 mg ml 21 was added to the cells for 120 min. Spinning at 300g for 8 min was followed by hypotonic treatment in pre-warmed 0.075 M KCl for 20 min at 37 uC. Cells were fixed in cold ethanol/acetic acid (3:1) and airdried slides were prepared.
The M-FISH hybridization was performed with a panel of mouse M-FISH probes (21 3 Mouse mFISH probe kit, MetaSystems) according to the manufacturer's instructions. In brief, the probes were denatured at 75 uC for 5 min. and pre-annealed at 37 uC for 30 min. Slides were incubated in 0.1 3 SSC for 1 min, denatured in 0.07N NaOH at room temperature for 1 min, quenched in 0.1 3 SSC at 4 uC and 2 3 SSC at 4 uC for 1 min each, dehydrated in an ethanol series and air dried. M-FISH probe was applied onto the slides and hybridization was performed for 48 h in a humidified chamber at 37 uC. Following hybridization, the slides were washed in 0.4 3 SSC at 72 uC for 2 min, followed by a wash in 2 3 SSC, 0.05% Tween20 at room temperature for 2 min. Counterstaining was performed using DAPI (4',6diamidino-2-phenylindole) and mounted with phenylenediamine.
Slides were visualized using a Leica DMRXA-RF8 epifluorescence microscope equipped with special filter blocks (Chroma Technology). For image acquisition, a Sensys CCD camera (Photometrics) with a Kodak KAF 1400 chip was used. Both the camera and microscope were controlled with Leica Q-FISH software (Leica Microsystems Imaging Solutions). Images were analysed using the Leica MCK-Software package (Leica Microsystems Imaging Solutions). Western blotting, flow cytometry and antibodies. Western blotting was performed according to standard protocols. In brief, tissues were either snap frozen in liquid nitrogen and homogenized, or dissociated into single cells using 100 mm nylon mesh (CellStrainer, BD Falcon). Protein was extracted using standard protein lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 ) supplemented with a protease inhibitor cocktail (Complete Roche Diagnostics) and quantified using a Bradford Protein Assay (Bio-Rad). Proteins were separated on a polyacrylamide gel (ProteanIII, Bio-Rad) and transferred to a PVDF membrane (Immobilon-F, Millipore). Protein bands were resolved using fluorochrome-conjugated secondary antibodies on an Odyssey scanner (Licor). All western blot experiments were replicated at least twice.
For the analysis of pAkt and pS6 induction after CCL25 stimulation, shPten T-ALL cells derived from spleen tissues of tumour-bearing shPten mice and adapted to cell culture were either left untreated or treated with Dox for 4 days to reactivate PTEN, starved over night at 0.5% FBS and then treated with CCL25 for the indicated time points. For the CCL25 stimulation assay of the human T-ALL cell lines HBP-ALL and TALL1, the cells were infected with a retroviral vector coexpressing a shPTEN. 1522 or Renilla control shRNA and a puromycin-resistance cassette linked to GFP. After selection with puromycin for a 5 days, the cells were starved over night at 0.1% FBS and then treated with CCL25 for 15 min before collecting for immunoblot analysis.
For flow cytometric analysis (FACS), single-cell suspensions were brought to a concentration of 1310 6 cells per ml in FACS-buffer (PBS, pH 7.4, 1% BSA) and stained with the indicated antibodies as per the manufacturer's protocol. After washing, cells were measured on a Guava easyCyte (Millipore) or LSRII (BectonDickinson) FACS machine. Cell sorting was performed on a BectonDickinson FACSAria II machine. For intracellular pS6 measurement, cells were fixed with 2% paraformaldehyde and permeabilized with methanol before staining for pS6 as previously described 40 . CCL25 expression. For quantification of CCL25 chemokine levels in the intestine of Rag1 2/2 and NCr nude mice, parts of the jejunum and ileum were dissected from euthanized animals, cleaned in phosphate-buffered saline (pH 7.4), and snap frozen in liquid nitrogen. Tissues were homogenized in T-PER Tissue Protein Extraction Buffer (Pierce Biotechnology) supplemented with a protease inhibitor cocktail (Complete Roche Diagnostics) to prevent degradation of proteins during and after homogenization. Protein extracts were centrifuged at 20,000 r.c.f., supernatants were collected, and total protein content was assayed using the Bradford Protein Assay (Bio-Rad). Tissue homogenates were analysed for CCL25 protein levels by a 3-step sandwich enzyme-linked immunosorbent assay as per the manufacturer's instructions (R&D Systems).
Transwell migration assay. For transwell migration assays, 5 3 10 5 cells with or without Dox treatment were starved in RPMI containing 1% serum for 12h overnight and the next day 3 3 10 5 viable cells were plated in 200 ml in the upper part of a 24-well Boyden chamber insert with a membrane pore size of 8 mm (Greiner Bio-One). The lower part of the chamber was filled with 600 ml medium containing 500 ng ml 21 recombinant CCL25 (R&D Systems). Following a 4 h incubation at 37 uC and 7.5% CO 2 , migrating cells in the lower chamber were counted using a Guava easyCyte cell counter (Millipore). Transwell migration experiments were run in triplicate for each condition on two independent tumour isolates. Histology and IHC. Organ samples were fixed in fresh 4% paraformaldehyde at 4 uC overnight and further subjected to routine histological procedures for embedding in paraffin. 5-mm sections of the samples from at least three different animals per group were placed on microscopic slides next to one another to enable crosscomparison within a slide after H&E staining or IHC staining with the antibodies indicated. Antibodies used were GFP (D5.1) XP, PTEN (D4.3), p-AKT (S473) (D9E), p-ribosomal protein S6 (S235/236) (D57.2.2E), cleaved caspase 3 (Asp175) (all: Cell Signaling Technologies), Ki67 (VP-K451, Vector Laboratories) and CD3 (A0452) (DAKO). Stained slides were scanned with a Pannoramic Scan 250 Flash or MIDI system and images acquired using Pannoramic Viewer 1.15.2 (both: 3DHistech). Additional images were taken on a Zeiss Axio Imager.Z2 system. shCcr9 hairpin design and competition experiments. shRNAs targeting Ccr9 were generated as previously described 33 and cloned into a retroviral vector coexpressing mCherry (LMN-C 38 ). Knockdown of Ccr9 was quantified in a murine T-ALL cell line by flow cytometry using an Alexa 647-conjugated antibody against murine CCR9 (clone 9B1, eBiosciences). The two most efficient shRNAs, shCcr9.904 (97mer: 59-TGCTGTTGACAGTGAGCGCAAGGATAAGAATGCCAAGCTATAG TGAAGC CACAGATGTATAGCTTGGCATTCTTATCCTTATGCCTACTG CCTCGGA-39) and shCcr9.2357 (97-mer: 59-TGCTGTTGACAGTGAGCGCCC CAACAGTTTACAACCTTTAT AGTGAAGCCACAGATGTATAAAGGTTGT AAACTGTTGGGATGCCTACTGCCTCGGA-39), were used for subsequent assays. For the infection of tumour cells, eGFP 1 shPten T-ALL cells were grown on OP9-DL1 feeders in the presence of 10 ng ml 21 mIL7 in Optimem Glutamax medium (Gibco/Life Technologies) and infected with either shCcr9 or shRenilla control shRNAs. Approximately 0.75 3 10 6 infected shPten cells (20-30% mCherry 1 ) were transplanted into recipient Rag1 2/2 mice irradiated with 450 rad, and monitored for disease development. Diseased mice were euthanized, and spleen, bone marrow, liver, lung, small intestine and kidney tissues were collected and minced to generate single-cell suspensions for flow cytometric measurement of eGFP-and mCherry-positive cell fractions. Relative mCherry fractions from different organs were determined by normalizing to the spleen fraction as 100%. CCR9 inhibitor treatment. The CCR9 inhibitor CCX8037 was kindly provided by Chemocentryx 25, 41 . For cell culture treatment, different concentrations of CCX8037 were used as indicated. For in vivo experiments, mice were treated with 30 mg kg 21 inhibitor or vehicle (HPMC 1%) administered via subcutaneous injection every 12 h (CCX8037). Clonality analysis of murine shPten tumours. Clonality analysis by PCR amplification and sequencing of murine TCRb sequences was performed as previously described 42 . In brief, clonality was assayed at V-DJ and D-J rearrangements in a mixure of 20 family-specific upstream primers located within Vb gene segments, consensus primers located 59 of Db1 and Db2 gene segments and consensus downstream primers located 39 of Jb1 and Jb2 gene segments. PCR products were analysed by direct Sanger sequencing. Profiling of Notch1 mutations by Sanger sequencing. Vav-tTA;shPten tumours were analysed for Notch1 hotspot mutations located in Exon 26, 27 and 34 by Sanger sequencing as described previously 43 , including one new oligonucleotide primer pair: Ex34B-f: 59-GCCAGTACAACCCACTACGG-39; Ex34B-r: 59-CCTGAAG CACTGGAA-AGGAC-39. RNA-seq data generation and bioinformatic analysis. Total RNA was extracted from shPten leukaemic cells on/off Dox purified by sorting for CD4 expression with magnetic beads using Trizol (Invitrogen). RNA quality and quantity were assessed using Agilent RNA 6000 Nano Chip (Agilent Technologies) and Qubit 2.0 fluorometer (Life Technologies), respectively. RNA-seq libraries were prepared from 1 mg of total RNA per sample using the TruSeq RNA Sample Preparation Kit v2 (Illumina) following the standard protocol with slight modification (10 PCR cycles). RNA-seq library quality and quantity were assessed using the Agilent DNA 1000 Chip and Kappa Library qPCR kit (Kappa Biosystems). Libraries were clustered on an Illumina cBot and sequenced on the HiSeq2000 (2 3 100-bp reads) using Illumina chemistry (Illumina).
The RNA-seq paired-end reads were mapped to the mouse mm9 genome and its corresponding transcript sequences using an in-house mapping and quality assessment pipeline 15 . Transcript expression levels were estimated as fragments per kilobase of transcript per million mapped reads (FPKM) and gene FPKMs were computed by summing the transcript FPKMs for each gene using the Cuffdiff2 program 44 .
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We called a gene 'expressed' in a given sample if it had a FPKM value $ 0.5 based on the distribution of FPKM gene expression levels and excluded genes that were not expressed in any sample from the final gene expression data matrix for downstream analysis. Differentially expressed genes were identified using LIMMA 45 and false discovery rate was estimated by Benjamini-Hochberg method 46 . GSEA 47, 48 and the Database for Annotation, Visualization and Integrated Discovery (DAVID v6.7) 49 were used to assess pathway enrichment. All mouse RNA-seq data sets are submitted to the European Nucleotide Archive (ENA) and can be accessed under the accession number PRJEB5498 at http://www.ebi.ac.uk/ena/data/view/PRJEB5498. GSEA. To test for mouse shPten signature enrichment in PTEN-disrupted human T-ALL, we established a shPten-dependent signature using the 100 most upregulated genes in shPten T-ALL samples (untreated, n 5 3) against PTEN-restored samples (Dox-treated, n 5 4) samples. Publicly available human T-ALL gene expression profiles (GSE28703, n 5 47) were processed using RMA (quantile normalization) and supervised for PTEN status (PTEN disrupted including PTEN deletion, mutation or both, n 5 10; PTEN wild-type, n 5 37) according to the published sample genetic features annotation 15 . Statistical significance of GSEA results was assessed using 1,000 sample permutations. For enrichment of human PTEN T-ALL signature in mouse shPten T-ALL (Dox-off) profiles against PTEN-restored (Doxon) profiles, a human PTEN-disrupted signature was generated by including the 100 most upregulated genes in PTEN-disrupted versus PTEN-wild type T-ALL samples. Mouse genes were ranked by supervising untreated to Dox-treated shPten T-ALL. Statistical significance of human PTEN-disrupted signature enrichment was assessed using 1,000 gene set permutations. Genomic tumour DNA was analysed on Affymetrix CGH SNP arrays and compared to normal skin tissue. x axis indicates genomic coordinate and y axis represents log 2 (tumour/germline). d, Schematic of the murine NOTCH1 protein generated using protein paint (http://explore.pediatriccancer genomeproject.org/proteinPainter), highlighting the different NOTCH1 protein domains and the mutations detected in the murine shPten and Pten 2/2 T-ALL tumours. LETTER RESEARCH
